Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Baird Upgrades U.S. Bancorp to Outperform, Announces $52 Price Target

Baird Upgrades U.S. Bancorp to Outperform, Announces $52 Price Target

Baird analyst David George upgrades U.S. Bancorp (NYSE:USB) from Neutral to Outperform and announces $52 price target.

byBenzinga Newsdesk

March 20, 2023

1 minute read

Baird analyst David George upgrades U.S. Bancorp (NYSE:USB) from Neutral to Outperform and announces $52 price target.

Inverse Jim Cramer ETF Outperforms Market Just 2 Weeks After Launch

By Mehab Qureshi

March 15, 1:18 AM

The Inverse Cramer Tracker ETF (BATS: SJIM) is already outperforming the market just two weeks after its debut.

BTC

1st Source Q2 EPS $1.18 Beats $1.06 Estimate

By Benzinga Newsdesk

July 21, 4:00 PM

1st Source (NASDAQ:SRCE) reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $1.06 by 11.32 percent. This is a 0.84 percent decrease over earnings of $1.19 per share from the same

SRCE

Donald Trump To Get Endorsement From Blackstone CEO Steve Schwarzman: Report

By Nabaparna Bhattacharya

May 25, 12:27 PM

Blackstone CEO Steve Schwarzman reportedly pledges to back Donald Trump, signaling a resurgence of support from major donors.

Analyst Ratings

The Latest Analyst Ratings for Gracell Biotechnologies

By Benzinga Insights

October 19, 9:00 AM

Analysts have provided the following ratings for Gracell Biotechnologies (NASDAQ:GRCL) within the last quarter: Bullish Somewhat Bullish Indifferent…

GRCL

Baird Upgrades U.S. Bancorp to Outperform, Announces $52 Price Target

Related Posts

Inverse Jim Cramer ETF Outperforms Market Just 2 Weeks After Launch

1st Source Q2 EPS $1.18 Beats $1.06 Estimate

Donald Trump To Get Endorsement From Blackstone CEO Steve Schwarzman: Report

The Latest Analyst Ratings for Gracell Biotechnologies